Skip to main content
Arctic Bioscience logo

Arctic Bioscience — Investor Relations & Filings

Ticker · ABS ISIN · NO0010859580 LEI · 549300Z2HW6I989Q2C78 OL Manufacturing
Open in API
Filings indexed 422 across all filing types
Latest filing 2025-01-13 Capital/Financing Update
Country NO Norway
Listing OL ABS

About Arctic Bioscience

https://arctic-bioscience.com/

Arctic Bioscience is a biotechnology company that develops and commercializes pharmaceutical and nutraceutical products derived from marine membrane lipids. The company utilizes proprietary technology to extract bioactive compounds from herring roe, sourced from sustainable, MSC-certified fisheries. Its nutraceutical product line, marketed under the brand name Romega, consists of high-DHA Omega-3 phospholipid extracts. The pharmaceutical division is focused on developing a novel drug candidate for the treatment of mild-to-moderate psoriasis, aligning with its mission to create therapies for autoimmune disorders. The company's work is supported by extensive research and development to validate the efficacy of its marine-based ingredients.

Recent filings

Filing Released Lang Actions
Arctic Bioscience - finansiert til positiv kontantstrøm
Capital/Financing Update Classification · 98% confidence The document announces the securing of new financing totaling 30 million Norwegian Kroner, structured as a long-term loan from Innovation Norway and a long-term convertible loan from a consortium of investors. It details the terms of these loans, including interest rates, maturity, and conversion clauses. This content directly relates to the company's fundraising and capital structure changes. Therefore, it fits the definition of 'Capital/Financing Update' (CAP). The document is short and appears to be a press release or regulatory announcement, not a comprehensive report, confirming it is an announcement type.
2025-01-13 Norwegian
Arctic Bioscience - funded to cash positive
Capital/Financing Update Classification · 98% confidence The document announces that Arctic Bioscience has secured NOK 30 million in funding through a combination of a loan from Innovation Norway and a convertible loan from investors. It details the terms of this financing, including interest rates and conversion clauses. This content directly relates to the company's fundraising and capital structure changes. Therefore, it fits the definition of 'Capital/Financing Update' (CAP). The document is short and appears to be a press release or official notice, not a comprehensive report like a 10-K or IR.
2025-01-13 English
Arctic Bioscience - Minutes of the Extraordinary General Meeting
AGM Information Classification · 99% confidence The document text is explicitly titled 'PROTOKOLL FRA EKSTRAORDINÆR GENERALFORSAMLING' (Minutes from Extraordinary General Meeting) and details the proceedings, attendees, votes, and resolutions passed during a meeting of shareholders. This directly corresponds to the definition of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting (or Extraordinary General Meeting, as this is a formal record of the meeting).
2024-11-19 Norwegian
Arctic Bioscience - Protokoll fra ekstraordinær generalforsamling
AGM Information Classification · 99% confidence The document text is explicitly titled 'PROTOKOLL FRA EKSTRAORDINÆR GENERALFORSAMLING' (Minutes from Extraordinary General Meeting) and details the proceedings, attendees, votes, and resolutions passed during a meeting of shareholders. This directly corresponds to the definition of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting (or Extraordinary General Meeting, as this is a formal record of the meeting).
2024-11-19 Norwegian
Arctic Bioscience - Minutes of the Extraordinary General Meeting
AGM Information Classification · 99% confidence The document is explicitly titled 'Minutes of the Extraordinary General Meeting' and states that 'All the items on the agenda were addressed and approved.' It also mentions that the minutes are attached. An Extraordinary General Meeting (EGM) is a type of general meeting. The closest category covering meeting materials, especially those related to shareholder votes and meeting outcomes, is AGM Information (AGM-R). While 'Minutes' are often part of the final documentation, the context of an EGM aligns best with AGM-R, which covers presentations and materials shared during the Annual General Meeting (AGM). Since this is a record of the meeting's proceedings and outcomes, AGM-R is the most appropriate fit among the provided options, as there is no specific code for EGM minutes, and it relates directly to shareholder governance events.
2024-11-19 English
Arctic Bioscience - Protokoll fra ekstraordinær generalforsamling
AGM Information Classification · 98% confidence The document title is "Arctic Bioscience - Protokoll fra ekstraordinær generalforsamling" (Minutes from an Extraordinary General Meeting). The text confirms that an extraordinary general meeting was held, all agenda items were passed, and the minutes ("protokoll") are attached. This directly relates to the proceedings and outcomes of a shareholder meeting. The most appropriate category is AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting (AGM), and by extension, Extraordinary General Meetings (EGM) minutes/protocols. Although it is a protocol (minutes), which might suggest a regulatory filing (RNS), the specific nature of the content (EGM minutes) makes AGM-R a much better fit than the general fallback.
2024-11-19 Norwegian

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.